Blepharitis related to cetuximab treatment in an advanced colorectal cancer patient;Blefaritis asociada al tratamiento con cetuximab en adenocarcinoma colorrectal avanzado

Archivos de la Sociedad Espanola de Oftalmologia

Volumn 83, Issue 11, 2008, Pages 665-668

  Ramírez Soria, Ma Del Pilar ^a,b   Espana Gregori E ^a,c   Avino Martinez J ^a,b   Pastor Pascual, F ^a,b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b Servicio de Oftalmologia   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Blepharitis; Colorectal cancer; Epidermal growth factor receptor; Monoclonal antibodies

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; MONOCLONAL ANTIBODY;

ARTICLE; BLEPHARITIS; CASE REPORT; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; DISEASE COURSE; FEMALE; HUMAN; MIDDLE AGED;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLEPHARITIS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED;

EID: 58649117947     PISSN: 03656691     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Moertel CG. Chemotherapy for colorectal cancer. N Engl Med 1994; 330: 1136-1142.
2. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23: 2445-2459.
3. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
4. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of head and neck. N Engl J Med 2006; 354: 567-578.
5. Tonini G, Vincenzi B, Santini D, Olzi D, Cambiase A, Bonini S. Ocular toxicity related to cetuximab monotherapy in advanced colorectal cancer patient. J Natl Cancer Inst 2005; 97: 606-607.